Low Grade Serous Ovarian Cancer - Epidemiology Forecast

List of Tables

Low Grade Serous Ovarian Cancer (LGSOC) Insights and Trends

LGSOC is a rare, indolent, relatively chemoresistant subtype (~5-10% of serous ovarian cancers) that is biologically distinct from high-grade disease and frequently characterized by RAS/MAPK pathway alterations.
Epithelial tumors make up over 90% of malignant ovarian neoplasms, and HGSOC dominates the epithelial group (~70%). LGSOC accounts for only about 8% of serous cases, which is why the addressable pool is small and why estimates are sensitive to the histotype split used.
Ovarian cancer incident cases in the 7MM were ~63,400 in 2025 and are projected to increase during the forecast period.
In EU4 and the UK, the maximum number of cases in low grade ovarian cancer are from RAS/RAF/MAPK main pathway, followed by KRAS subtype.

Low Grade Serous Ovarian Cancer (LGSOC) Epidemiology Forecast in the 7MM

2025 Prevalent Cases of LGSOC: ~ 3,300
2036 Projected Prevalent Cases of LGSOC: ~ XXXX
LGSOC Growth Rate (2026-2036): ~0.1% CAGR

DelveInsight's 'Low Grade Serous Ovarian Cancer (LGSOC) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the LGSOC, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Low Grade Serous Ovarian Cancer (LGSOC) Understanding and Diagnosis Algorithm

Low Grade Serous Ovarian Cancer (LGSOC) Overview

LGSOC is a rare and distinct histologic subtype of epithelial ovarian cancer, accounting for a small proportion of ovarian malignancies and differing substantially from High Grade Serous Ovarian Cancer (HGSOC) in its biology, clinical behavior, and treatment response. LGSOC is characterized by relatively slow tumor growth but a persistent risk of recurrence and typically occurs in younger women than HGSOC. The disease is frequently associated with alterations in the RAS/MAPK signaling pathway, including KRAS, NRAS, and BRAF mutations. Despite its more indolent course, LGSOC is generally less responsive to conventional platinum-based chemotherapy, making cytoreductive surgery, endocrine therapy, and targeted approaches important components of disease management, particularly in recurrent or advanced disease.

Low Grade Serous Ovarian Cancer (LGSOC) Diagnosis

Diagnosis of LGSOC requires histopathologic confirmation following surgical resection or biopsy. Microscopically, tumors are characterized by uniform cells with relatively low-grade nuclear atypia, papillary or micropapillary architecture, and often psammoma bodies. Immunohistochemistry is used to support the diagnosis and distinguish LGSOC from other ovarian cancer subtypes, with markers such as PAX8, WT1, and estrogen receptor commonly evaluated. Molecular testing can further characterize the tumor, particularly for KRAS, NRAS, and BRAF/MAPK pathway alterations, and may increasingly guide treatment selection. Imaging modalities such as transvaginal ultrasound, CT, and MRI are used to assess the primary tumor, disease extent, and metastatic involvement, while CA-125 may be used as a supportive biomarker for disease monitoring but is not sufficiently specific for diagnosis.

Low Grade Serous Ovarian Cancer (LGSOC) Epidemiology

Key Findings from Low Grade Serous Ovarian Cancer (LGSOC) Epidemiological Analysis and Forecast

The total number of incident cases of LGSOC in the 7MM were ~3,300 in 2025, which is expected to increase by 2036.
In 2025, the highest number of incident cases of LGSOC was observed in the United States, with ~1,200 cases, followed by the UK, which accounted for 500 cases.
The United States accounted for ~33% incident cases of ovarian cancer in 2025.
The incident cases of ovarian cancer were highest in the United States followed by Japan, and lowest in Spain in 2025.
In 2025, the total cases of LGSOC by type in Japan were highest in LGSOC Advanced-Stage (III-IV) (~80) followed by LGSOC Early Stage (I-II).
RAS/RAF/MAPK/ main pathway accounted for the largest share (~50%) of biomarker-specific LGSOC incident cases in 2025 in United States followed by KRAS (~20%), and smallest share was accounted by BRCA1/2.

Scope of the Report:

The report covers a segment of a descriptive overview of LGSOC, explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Low Grade Serous Ovarian Cancer (LGSOC) Patient Population Forecast

Report Key Strengths

Epidemiology-based (Epi-based) Bottom-up Forecasting
11-year Forecast
Patient Burden Trends (by Geography)

FAQs:

What are the disease risks, burdens, and unmet needs of LGSOC? What will be the growth opportunities across the 7MM concerning the patient population with LGSOC?
What is the historical and forecasted LGSOC patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Product Code: DIEI1752

1. Key Insights

2. Report Introduction

3. Executive Summary of LGSOC

4. Epidemiology Methodology of LGSOC

5. Low Grade Serous Ovarian Cancer Epidemiology Overview at a Glance

5.2. Patient Share (%) Distribution of LGSOC in 2025 in the 7MM
5.3. Patient Share (%) Distribution of LGSOC in 2036 in the 7MM

6. Disease Background and Overview

6.1. Introduction
6.2. Signs and Symptoms of LGSOC
6.3. Risk Factors and Causes of LGSOC
6.4. Stages of LGSOC
6.5. Pathology of LGSOC
6.6. Molecular Changes in LGSOC
6.7. Diagnosis
6.8. Differential Diagnosis

7. Epidemiology and Patient Population of 7MM

7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Total Incident Cases of Low Grade Serous Ovarian Cancer in the 7MM
7.4. The United States
- 7.4.1. Ovarian Cancer Total Incident Cases in the United States
- 7.4.2. LGSOC Total Incident Cases in the United States
- 7.4.3. LGSOC Type-specific Incident Cases in the United States
- 7.4.4. LGSOC Stage-specific Incident Cases in the United States
- 7.4.5. LGSOC Biomarker-specific Incident Cases in the United States
- 7.4.6. LGSOC Treated Cases in the United States
7.5. EU4 and the UK
- 7.5.1. Germany
  - 7.5.1.1. Ovarian Cancer Total Incident Cases in Germany
  - 7.5.1.2. LGSOC Total Incident Cases in Germany
  - 7.5.1.3. LGSOC Type-specific Incident Cases in Germany
  - 7.5.1.4. LGSOC Stage-specific Incident Cases in Germany
  - 7.5.1.5. LGSOC Biomarker-specific Incident Cases in Germany
  - 7.5.1.6. LGSOC Treated Cases in Germany
- 7.5.2. France
  - 7.5.2.1. Ovarian Cancer Total Incident Cases in France
  - 7.5.2.2. LGSOC Total Incident Cases in France
  - 7.5.2.3. LGSOC Type-specific Incident Cases in France
  - 7.5.2.4. LGSOC Stage-specific Incident Cases in France
  - 7.5.2.5. LGSOC Biomarker-specific Incident Cases in France
  - 7.5.2.6. LGSOC Treated Cases in France
- 7.5.3. Italy
  - 7.5.3.1. Ovarian Cancer Total Incident Cases in Italy
  - 7.5.3.2. LGSOC Total Incident Cases in Italy
  - 7.5.3.3. LGSOC Type-specific Incident Cases in Italy
  - 7.5.3.4. LGSOC Stage-specific Incident Cases in Italy
  - 7.5.3.5. LGSOC Biomarker-specific Incident Cases in Italy
  - 7.5.3.6. LGSOC Treated Cases in Italy
- 7.5.4. Spain
  - 7.5.4.1. Ovarian Cancer Total Incident Cases in Spain
  - 7.5.4.2. LGSOC Total Incident Cases in Spain
  - 7.5.4.3. LGSOC Type-specific Incident Cases in Spain
  - 7.5.4.4. LGSOC Stage-specific Incident Cases in Spain
  - 7.5.4.5. LGSOC Biomarker-specific Incident Cases in Spain
  - 7.5.4.6. LGSOC Treated Cases in Spain
- 7.5.5. The United Kingdom
  - 7.5.5.1. Ovarian Cancer Total Incident Cases in the United Kingdom
  - 7.5.5.2. LGSOC Total Incident Cases in the United Kingdom
  - 7.5.5.3. LGSOC Type-specific Incident Cases in the United Kingdom
  - 7.5.5.4. LGSOC Stage-specific Incident Cases in the United Kingdom
  - 7.5.5.5. LGSOC Biomarker-specific Incident Cases in the United Kingdom
  - 7.5.5.6. LGSOC Treated Cases in the United Kingdom
7.6. Japan
- 7.6.1. Ovarian Cancer Total Incident Cases in Japan
- 7.6.2. LGSOC Total Incident Cases in Japan
- 7.6.3. LGSOC Type-specific Incident Cases in Japan
- 7.6.4. LGSOC Stage-specific Incident Cases in Japan
- 7.6.5. LGSOC Biomarker-specific Incident Cases in Japan
- 7.6.6. LGSOC Treated Cases in the United States

8. Patient Journey of LGSOC

9. KOL Views

9.1. Expert/KOL Interview Highlights

10. Appendix

10.1. Bibliography
10.2. Report Methodology

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

Product Code: DIEI1752

List of Tables

Table 1: Summary of LGSOC Epidemiology (2025-2036)
Table 2: Total Incident Cases of LGSOC in the 7MM (2022-2036)
Table 3: Total Incident Cases of Ovarian Cancer in the United States (2022-2036)
Table 4: Type-specific Cases of Low grade Ovarian Serous Cancer in the United States (2022-2036)
Table 5: Stage-specific Cases of LGSOC in the United States (2022-2036)
Table 6: Biomarker-specific Cases of LGSOC in the United States (2022-2036)
Table 7: LGSOC Treated Patient Pool in the United States (2022-2036)
Table 8: Total Incident Cases of Ovarian Cancer in EU4 and the UK (2022-2036)
Table 9: Type-specific cases of LGSOC in Germany (2022-2036)
Table 10: Type-specific cases of LGSOC in France (2022-2036)
Table 11: Type-specific cases of LGSOC in Italy (2022-2036)
Table 12: Type-specific cases of LGSOC in Spain (2022-2036)
Table 13: Type-specific cases of LGSOC in the UK (2022-2036)
Table 14: Type-specific cases of LGSOC in EU4 and the UK (2022-2036)
Table 15: Stage-specific Cases of LGSOC in Germany (2022-2036)
Table 16: Stage-specific Cases of LGSOC in France (2022-2036)
Table 17: Stage-specific Cases of LGSOC in Italy (2022-2036)
Table 18: Stage-specific Cases of LGSOC in Spain (2022-2036)
Table 19: Stage-specific Cases of LGSOC in the UK (2022-2036)
Table 20: Stage-specific Cases of LGSOC in EU4 and the UK (2022-2036)
Table 21: Biomarker-specific Cases of LGSOC in Germany (2022-2036)
Table 22: Biomarker-specific Cases of LGSOC in France (2022-2036)
Table 23: Biomarker-specific Cases of LGSOC in Italy (2022-2036)
Table 24: Biomarker-specific Cases of LGSOC in Spain (2022-2036)
Table 25: Biomarker-specific Cases of LGSOC in the UK (2022-2036)
Table 26: Biomarker-specific Cases of LGSOC in EU4 & the UK (2022-2036)
Table 27: LGSOC Treated Patient Pool in Germany (2022-2036)
Table 28: LGSOC Treated Patient Pool in France (2022-2036)
Table 29: LGSOC Treated Patient Pool in Italy (2022-2036)
Table 30: LGSOC Treated Patient Pool in Spain (2022-2036)
Table 31: LGSOC Treated Patient Pool in the UK (2022-2036)
Table 32: LGSOC Treated Patient Pool in EU4 & the UK (2022-2036)
Table 33: Total Incident Cases of Ovarian Cancer in Japan (2022-2036)
Table 34: Type-specific Cases of Low grade Ovarian Serous Cancer in Japan (2022-2036)
Table 35: Stage-specific Cases of LGSOC in Japan (2022-2036)
Table 36: Biomarker-specific Cases of Low grade Ovarian Serous Cancer in Japan (2022-2036)
Table 37: LGSOC Treated Patient Pool in Japan (2022-2036)

List of Figures

Figure 1: Total Incident Cases of LGSOC in the 7MM (2022-2036)
Figure 2: Total Incident Cases of Ovarian Cancer in the United States (2022-2036)
Figure 3: Type-specific Cases of Low grade Ovarian Serous Cancer in the United States (2022-2036)
Figure 4: Stage-specific Cases of LGSOC in the United States (2022-2036)
Figure 5: Biomarker-specific Cases of LGSOC in the United States (2022-2036)
Figure 6: LGSOC Treated Patient Pool in the United States (2022-2036)
Figure 7: Total incident Cases of Ovarian Cancer in EU4 and the UK (2022-2036)
Figure 8: Type-specific Cases of Low grade Ovarian Serous Cancer in EU4 and the UK (2022-2036)
Figure 9: Stage-specific Cases of LGSOC in EU4 and the UK (2022-2036)
Figure 10: Biomarker-specific Cases of LGSOC in EU4 and the UK (2022-2036)
Figure 11: LGSOC Treated Patient Pool in EU4 and the UK (2022-2036)
Figure 12: Total Incident Cases of Ovarian Cancer in Japan (2022-2036)
Figure 13: Type-specific Cases of Low grade Ovarian Serous Cancer in Japan (2022-2036)
Figure 14: Stage-specific Cases of LGSOC in Japan (2022-2036)
Figure 15: Biomarker-specific Cases of LGSOC in Japan (2022-2036)
Figure 16: LGSOC Treated Patient Pool in Japan (2022-2036)

Low Grade Serous Ovarian Cancer - Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

Low Grade Serous Ovarian Cancer (LGSOC) Insights and Trends

Low Grade Serous Ovarian Cancer (LGSOC) Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of LGSOC

4. Epidemiology Methodology of LGSOC

5. Low Grade Serous Ovarian Cancer Epidemiology Overview at a Glance

6. Disease Background and Overview

7. Epidemiology and Patient Population of 7MM

8. Patient Journey of LGSOC

9. KOL Views

10. Appendix

11. DelveInsight Capabilities

12. Disclaimer

13. About DelveInsight

List of Tables

List of Figures